Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: A pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials

Journal of Clinical Psychiatry

Volumn 70, Issue 10, 2009, Pages 1365-1371

  Soares, Claudio N ^a   Kornstein, Susan G ^b   Thase, Michael E ^c   Jiang, Qin ^d   Guico Pabia, Christine J ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b Virginia Commonwealth University   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILY LIFE; FEMALE; FUNCTIONAL ASSESSMENT; HAMILTON SCALE; HUMAN; LEISURE; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL LIFE; SOMNOLENCE; SWEATING; WELLBEING; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; MALE; PLACEBOS; PSYCHOMETRICS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 72849134182     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05133blu     Document Type: Article

References (36)

1. Adler DA, McLaughlin TJ, Rogers WH, et al. Job performance deficits due to depression. Am J Psychiatry. 2006;163(9):1569-1576. PubMed doi:10.1176/appi.ajp.163.9.1569
2. Lerner D, Adler DA, Chang H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv. 2004;55(12):1371-1378. PubMed doi:10.1176/appi.ps.55.12.1371 (Pubitemid 39577972)
3. McIntyre RS, Wilkins K, Gilmour H, et al. The effect of bipolar I disorder and major depressive disorder on workforce function. Chronic Dis Can. 2008;28(3):84-91. PubMed (Pubitemid 351912067)
4. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436- 1442. PubMed doi:10.1016/S0140-6736(96)07495-8
5. Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008;108(1-2):49-58. PubMed doi:10.1016/j.jad.2007.06.014
6. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 Study. JAMA. 1995;274(19):1511-1517. PubMed doi:10.1001/jama.274.19.1511
7. World Health Organization. The World Health Report: 2001-Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001.
8. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105. PubMed doi:10.1001/jama.289.23.3095 (Pubitemid 37432885)
9. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US Workers. Am J Psychiatry. 2006;163(9):1561-1568. PubMed doi:10.1176/appi.ajp. 163.9.1561 (Pubitemid 44465756)
10. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000;57(4):375-380. PubMed doi:10.1001/archpsyc.57.4.375
11. Saarijärvi S, Salminen JK, Toikka T, et al. Health-related quality of life among patients with major depression. Nord J Psychiatry. 2002;56(4):261-264. PubMed doi:10.1080/08039480260242741
12. Weissman MM. Social functioning and the treatment of depression. J Clin Psychiatry. 2000;61(suppl 1):33-38. PubMed
13. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. PubMed doi:10.1176/appi.ajp.163.1.28
14. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;3182(2):657-665. doi:10.1124/jpet.106.103382 (Pubitemid 44061240)
15. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2008
16. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:113-115.
17. World Health Organization. Wellbeing Measures in Primary Health Care/the Depcare Project. Copenhagen, Denmark: WHO Regional Office for Europe; 1998.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. PubMed doi:10.1136/jnnp.23.1.56
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. PubMed doi:10.1192/bjp.134.4.382 (Pubitemid 9136500)
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
21. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243-253. PubMed doi:10.1097/YIC.0b013e32830cebed
22. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677-688. PubMed
23. Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(4):188-197. PubMed doi:10.1097/YIC. 0b013e32830263de
24. Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11):1663-1672. PubMed
25. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877-1890. PubMed doi:10.1185/03007990802161923
26. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338-347. PubMed doi:10.1097/YIC.0b013e3281e2c84b
27. Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144-154. PubMed
28. Feiger AD, Tourian K, Rosas G, et al. A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2009;14(1):41-50. PubMed
29. Wyeth Pharmaceuticals. Wyeth Pharmaceuticals Study 223. http://www.clinicalstudyresults.org/documents/company-study-8588-0.pdf. Accessed June 8, 2009.
30. Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183-195. PubMed
31. Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19(4):313-324. PubMed doi:10.2165/00023210- 200519040-00004
32. Wise TN, Meyers AL, Desaiah D, et al. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry. 2008;10(4):270-275. PubMed
33. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93-105. PubMed (Pubitemid 27407503)
34. Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002;51(2):123-133. PubMed doi:10.1016/S0006-3223(01)01291-4 (Pubitemid 34127902)
35. Bech P, Lunde M, Und'en M. Social Adaptation Self-Evaluation Scale (SASS): psychometric analysis as outcome measure in the treatment of patients with major depression in the remission phase. Int J Psychiatry Clin Pract. 2002;6:141-146. doi:10.1080/136515002760276063
36. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608-619. PubMed